S17 Ep14: Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

About this episode

Dr. Alissa Cooper discusses recent advances in the treatment of relapsed small cell lung cancer and the challenges in clinical workflows.

In today’s episode, we spoke with Alissa Cooper, MD. Dr Cooper is a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Cooper discussed recent advances that have reshaped the treatment paradigm for small cell lung cancer (SCLC), particularly in the relapsed setting. She highlighted the FDA approval of tarlatamab-dlle (Imdelltra) , a DLL3-targeting T-cell engager, as one of the most impactful developments in recent years. Despite this progress, Cooper emphasized that the frontline standard of care has remained largely unchanged, continuing to rely on platinum-based chemotherapy in combination with immunotherapy. She noted that, although ongoing clinical trials are exploring biomarker-driven strategies and novel combinations, a more personalized first-line approach has yet to be established. The conversation also explored real-world treatment sequencing and decision-making at the point of relapse. Cooper explained that, whenever feasible, oncologists aim to enroll patients in clinical trials or initiate treatment with tarlatamab. However, logistical barriers, including trial…

People in this episode

Guests: Alissa Cooper, MD, Alissa Cooper

Topics covered

• small cell lung cancer
• treatment advances
• clinical trials
• personalized medicine
• oncology

Keywords

• SCLC
• FDA approval
• treatment paradigm
• clinical trials
• biomarker-driven strategies

Mentioned in this episode

Organizations: Dana-Farber Cancer Institute, Harvard Medical School

Products: tarlatamab-dlle, Imdelltra, lurbinectedin, Zepzelca

Places: Boston, Massachusetts

More episodes of OncLive® On Air

• S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD · June 10, 2026 · 10 min
• S17 Ep31: ASCO 2026 Plenary: RASolute 302 · June 8, 2026 · 11 min
• S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy · June 5, 2026 · 32 min
• S17 Ep29: Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD · June 1, 2026 · 30 min
• S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD · May 28, 2026 · 30 min
• S17 Ep27: Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD · May 27, 2026 · 16 min